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A commentary on 
A breath of fresh air on the mesenchyme: impact of impaired mesenchymal development on 
the pathogenesis of bronchopulmonary dysplasia 
by Chao C-M, El Agha E, Tiozzo C, Minoo P, Bellusci S. Front Med (2015) 2:27. doi: 10.3389/
fmed.2015.00027
Bronchopulmonary dysplasia (BPD) is a chronic lung disease of prematurity that is only now 
beginning to be understood at the molecular level. The review by Chao et al. (1) elegantly takes 
us through mouse and human lung development to identify possible mediators of the abnormal 
mesenchymal response characteristic of the disease. However, it quickly becomes clear that many 
aspects of BPD development seem to mimic chronic lung disease in adults. For example, secondary 
septa formation is a critical step in alveologenesis, with alveolar simplification in BPD thought to 
result from disordered septation. In the emphysematous adult lung, enlarged airspaces reminiscent 
of alveolar simplification are also seen; importantly, evidence suggests that many mediators thought 
to be important in BPD development are also important in COPD pathogenesis, such as wingless 
and int (Wnt) (2, 3), fibroblast growth factor (FGF) (4, 5), and sonic hedgehog (Shh) (6). Similarly, 
exuberant collagen and elastin deposition during alveologenesis bears remarkable similarity to the 
deposition of extracellular matrix proteins during adult lung fibrogenesis (7), although it is unclear 
whether the pattern and relative quantities of proteins are also similar. These observations, plus 
others, suggest a potential stereotypic lung injury response resulting in disrepair in adult lung and 
abnormal development in the neonate.
Despite the differences in etiology, both BPD and chronic adult lung injury are characterized 
by elevated expression and activity of transforming growth factor (TGF)-β, perhaps the most well-
known profibrotic cytokine. Implicated in epithelial–mesenchymal transition (EMT) (8), myofi-
broblast differentiation (9), and epithelial apoptosis (10), TGF-β overexpression may be pathogenic 
for BPD, emphasizing the critical need for TGF-β regulation during fetal lung development (11). 
Similarly, in adult lung, TGF-β overexpression is maladaptive, resulting in fibrosis that has been 
likened to recapitulation of developmental programs (12). Understanding how dysregulated TGF-β 
activity perturbs both normal development and postnatal lung repair has yet to be determined, but 
side-by-side comparisons of the role of mesenchymal cells in lung development and disease will 
likely shed further insight.
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An intriguing aspect of the review by Chao et al. is the sup-
portive role of the lipofibroblasts (LIFs), the interstitial fibroblasts 
identified in rodent lungs containing cytoplasmic lipid droplets 
(13) thought to be important in alveolar epithelial cell surfactant 
production. Despite one manuscript showing the existence of 
LIFs in human lung (14), controversy still remains (15) about the 
existence of this cell in humans. While LIFs seem to contribute to 
secondary septation in developing rodent lungs through transfer 
of lipids to Type II alveolar epithelial cells (16), their role in 
the adult rodent lung (if any) remains unclear. To be certain if 
LIFs are developmentally important and potentially reparative 
mesenchymal cells of the lung, identifying them in human lung 
of any age would be of paramount importance. Similarly, it will 
be important to determine whether LIFs are truly a separate 
type of mesenchymal cell or whether they are simply interstitial 
fibroblasts that uptake lipid droplets for transfer to alveolar epi-
thelium. Currently, there are few known markers of LIFs, such as 
platelet-derived growth factor receptor (PDGFR)-α and peroxi-
some proliferator-activated receptor (PPAR)-γ (17), but these are 
not specific for LIFs. More work in this area will obviously be 
necessary.
Mesenchymal–epithelial crosstalk, as described above for LIFs 
and type II alveolar epithelial cells, is obviously important for lung 
development, as nicely illustrated by Chao and colleagues (1). 
However, less is known about the contribution of the endothelium, 
and more specifically mesenchymal–endothelial interactions, in 
the development of chronic lung diseases, including BPD. Clearly, 
the transformation of a double vasculature to a single capillary 
system in primary alveolar septae is integral to gas exchange in 
the developing lung, as pointed out by Chao and colleagues. The 
development of this vasculature occurs through both angiogen-
esis and vasculogenesis. Along the same line, angiogenesis and 
vasculogenesis appear to be important in the development of 
certain adult chronic lung diseases, such as COPD, asthma, and 
idiopathic pulmonary fibrosis (IPF) (18–20). Indeed, nintedanib, 
a tyrosine kinase inhibitor that blocks vascular endothelial 
growth factor receptor, FGF receptor, and PDGFR, has recently 
gained approval around the world for treatment of IPF because of 
its effects on slowing the rate of decline of lung function (21). It is 
not yet known whether the salutary effect of nintedanib in IPF is 
related to its inhibitory effects on angiogenesis.
We have certainly learned much about BPD pathogenesis 
through elegant mouse modeling and human pathologic stud-
ies. However, there is still much to learn; murine studies, while 
informative, cannot take the place of knowledge generated in 
human samples of disease. Moreover, although mouse lung 
development occurs in a stereotypic fashion which has been well 
characterized, it is not proven that human lung development 
occurs entirely in the same way. Thus, better methods of studying 
human lung development need to be created and validated, with 
findings hopefully informing our understanding of chronic adult 
lung diseases as well.
As alluded to by Chao and colleagues (1), the incidence of BPD 
and its long-term effects appears to be on the rise as more prema-
ture infants survive owing to advances in supportive care. There 
are no definitive therapies for these patients. Just as research into 
the lung mesenchyme will surely enlighten our understanding of 
BPD, researchers of all chronic lung diseases are likely to gain 
better insights into disease pathogenesis and potentially pave 
the way for future therapies in numerous diseases. Impaired 
mesenchymal development and responses – it is not just for BPD.
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